A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer.
Trial Details
- NCT ID
- NCT06085664
- Phase
- PHASE1 / PHASE2
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Prostate Cancer
- Interventions
- REGN5678
- Piflufolastat F18
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Men ≥ 18 years of age
- Histologically documented Gleason 8 or greater prostatic adenocarcinoma in at least 3 biopsy cores and at least 8 mm of disease on a single core of…
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade of 0 or 1
- No evidence of metastatic disease as documented by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →